Dawn Boothe

About

Dr. Dawn Boothe graduated from Texas A&M University (TAMU) with a DVM degree in 1980. After an internship at Auburn University, she returned to TAMU to complete a master’s in physiology, a residency in small animal internal medicine (becoming board certified in 1985), and a PhRMA Fellowship and Ph.D. in Veterinary Clinical Pharmacology (1989). She is among the first class of diplomates in the American College of Veterinary Clinical Pharmacology. In 1990 she joined TAMU in the Department of Veterinary Physiology and Pharmacology, later joining the Anatomy, Physiology & Pharmacology and Clinical Sciences departments at Auburn University’s College of Veterinary Medicine. Here, Dr. Boothe directed the Clinical Pharmacology Laboratory, serving over 4000 national and international veterinary practices. Dr. Boothe retired from Auburn University in late 2022 and now contributes her knowledge on veterinary clinical pharmacology as a consultant/editor for the Veterinary Information Network.

Topic: Pharmacology

Small Animal Medicine

Sunday, June 11, 2023

3:30 PM-4:20 PM

Interpreting Culture and Susceptibility Data: The Best Bang for your Bug

Culture and susceptibility testing is increasingly needed to be able to effectively choose antimicrobials. However, this tool must be understood in the context of what it means, and what it does not mean. This session will address perks and pitfalls in both the individual patient as well as the use of population data to support therapeutic decisions.

4:30 PM-5:20 PM

Designing the Dosing Regimen: The MIC Is Still the KEY

The dosing regimen begins with choosing the most effective drug for your patient, which includes not only understanding “how susceptible” a drug is, but also how doses and intervals might be adjusted given the location of the infection and the relationship between drug concentrations and efficacy.

Monday, June 12, 2023

8:30 AM-9:20 AM

Compounding: What Is the big GIF? (Or How Is the FDA Going to Regulate Compounding of Drugs in Animals?)

The Food and Drug Administration has provided guidance as to how it plans to regulate the compounding of animal drugs from bulk substances. This session will focus on what this means—and does not mean—to the use of compounded drugs in non-food animals.

9:30 AM-10:20 AM

Medical Cannabinoids: Getting to Know the Products

Evidence of the efficacy of cannabidiol for treatment of a variety of disorders is becoming clear. However, efficacy begins with understanding how product selection might impact therapeutic success. This session will focus on a clinical pharmacologist’s perspective on unwinding some of the complexities associated with these products.

10:30 AM-11:20 AM

Nutraceuticals: Myth, Magic, or Must?

There is no such thing as an animal dietary supplement. Nonetheless, our clients use them and we use them. It is definitely a “buyer beware” market. This session will focus on considerations that should influence the use and purchase of supplements.

11:50 AM-12:40 PM

Antimicrobial Stewardship: Myths and Controversies Regarding Antimicrobial Therapy

Bactericidal or static? High or low dose? Short or long duration? Antimicrobial stewardship begins with addressing some of the unsubstantiated dogmas that have guided antimicrobial therapy.

12:50 PM-2:05 PM

The Impact of Antimicrobials on the Microbiota

It is not only the “bad” bacteria that are impacted by antimicrobial therapy. This session will explore the evidence, particularly in dogs, of the impact of antimicrobials on the normal microbiota. This will include defining terms and delineating the research approaches practitioners are likely to see in scientific reports.